Aileron Therapeutics, Inc. (ALRN)
ALRN moved a median of 0.00% 30 minutes after news, and -1.85% by the close. How ALRN actually reacts to news — the realized, point-in-time move the market made, measured across 105 labeled events over the last three years with zero look-ahead.
ALRN’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 24% | 95 |
| 30-min | 0.00% | 35% | 102 |
| 60-min | -1.83% | 31% | 104 |
| to close | -1.85% | 40% | 104 |
| Middle 50% of ALRN reactions | -2.92% to +0.92% |
|---|---|
| Median reaction (30-min) | 0.00% |
| Measured reactions | 105 |
Half of all Aileron Therapeutics, Inc. news events land between -2.92% and +0.92% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when ALRN moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to ALRN's baseline. Nothing else.
Recent ALRN events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Aileron Therapeutics Announces Rebranding to Rein Therapeutics | Press release | PR Newswire | +0.00% | +4.46% | |
| Form 8-K Rein Therapeutics, Inc. For: Jan 10 | SEC filing · Form 8-K | SEC EDGAR | — | — | |
| Aileron Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights | Press release | PR Newswire | +0.00% | -14.33% | |
| Form 10-Q Aileron Therapeutics, For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.00% | -14.33% | |
| Form 8-K Aileron Therapeutics, For: Nov 14 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -14.33% | |
| Aileron Therapeutics Announces Positive Topline Data from Cohort 2 of the Phase 1b Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis (IPF) | Press release | PR Newswire | +0.00% | -7.51% | |
| Aileron Therapeutics and Advancium Health Network Announce an Exclusive Option Agreement for the Acquisition of ALRN-6924 for Retinoblastoma | Press release | PR Newswire | +0.00% | +5.64% | |
| Aileron Therapeutics to Present Previously Announced Data from the Phase 1b Clinical Trial Evaluating Low-Dose LTI-03 in Idiopathic Pulmonary Fibrosis (IPF) at the 22nd International Colloquium on Lung and Airway Fibrosis | Press release | PR Newswire | +0.00% | +0.00% | |
| Aileron Therapeutics Completes Enrollment in Cohort 2 of the Ongoing Phase 1b Clinical Trial Evaluating LTI-03 in Idiopathic Pulmonary Fibrosis (IPF) | Press release | PR Newswire | -6.27% | -2.63% | |
| Form 8-K Aileron Therapeutics, For: Aug 20 | SEC filing · Form 8-K | SEC EDGAR | -3.46% | -3.85% | |
| Aileron Therapeutics to Present at the 8th Annual IPF Summit | Press release | PR Newswire | +7.34% | +10.09% | |
| Aileron Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights | Press release | PR Newswire | +0.00% | -15.38% | |
| Form 10-Q Aileron Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.00% | -15.38% | |
| Form 8-K Aileron Therapeutics, For: Aug 14 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -15.38% | |
| Aileron Therapeutics to Present at the Canaccord Genuity 44th Annual Growth Conference | Press release | PR Newswire | -1.75% | +1.32% | |
| Form 8-K Aileron Therapeutics, For: Jul 26 | SEC filing · Form 8-K | SEC EDGAR | -0.60% | -6.43% | |
| Form ARS Aileron Therapeutics, For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | — | +1.94% | |
| Form DEF 14A Aileron Therapeutics, For: Aug 20 | SEC filing · Form DEF | SEC EDGAR | — | +1.94% | |
| Form DEFA14A Aileron Therapeutics, | SEC filing · Form DEFA14A | SEC EDGAR | — | +1.94% | |
| Aileron Therapeutics to be Included in the Russell Microcap® Index | Press release | PR Newswire | +3.75% | +4.87% | |
| Form 8-K Aileron Therapeutics, For: Jun 05 | SEC filing · Form 8-K | SEC EDGAR | -2.31% | +1.54% | |
| Form 8-K Aileron Therapeutics, For: May 15 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -2.08% | |
| Aileron Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights | Press release | GlobeNewswire | +0.00% | -3.75% | |
| Form 10-Q Aileron Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +0.00% | -3.75% | |
| Form 8-K Aileron Therapeutics, For: May 15 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -3.75% | |
| Aileron Therapeutics to Present at Two Upcoming Investor Conferences | Press release | GlobeNewswire | +1.09% | -4.16% | |
| Aileron Therapeutics Announces Closing of Underwritten Registered Direct Offering of up to Approximately $40 Million | Press release | GlobeNewswire | +0.00% | +3.95% | |
| Aileron Therapeutics Announces Positive Data from Cohort 1 of the Phase 1b Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis (IPF) | Press release | GlobeNewswire | +3.94% | -3.48% | |
| Aileron Therapeutics Announces Pricing of Underwritten Registered Direct Offering Priced At-The-Market Under Nasdaq Rules of up to Approximately $40 Million | Press release | GlobeNewswire | +3.94% | -3.48% | |
| Form 8-K Aileron Therapeutics, For: May 01 | SEC filing · Form 8-K | SEC EDGAR | +3.94% | -3.48% | |
| Form S-8 Aileron Therapeutics, | SEC filing · Form S-8 | SEC EDGAR | -0.23% | -10.96% | |
| Form 10-K/A Aileron Therapeutics, For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -0.40% | -1.01% | |
| Aileron Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update | Press release | GlobeNewswire | +0.00% | +0.19% | |
| Form 10-K Aileron Therapeutics, For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +0.00% | +0.19% | |
| Form 8-K Aileron Therapeutics, For: Apr 15 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +0.19% | |
| Form NT 10-K Aileron Therapeutics, For: Dec 31 | SEC filing · Form NT | SEC EDGAR | +0.00% | +3.07% | |
| Form 8-K AILERON THERAPEUTICS For: Mar 25 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -12.14% | |
| Form 8-K AILERON THERAPEUTICS For: Mar 11 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +1.46% | |
| Aileron Therapeutics Announces CEO Transition | Press release | GlobeNewswire | — | -5.24% | |
| Form 8-K AILERON THERAPEUTICS For: Feb 29 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -0.57% | |
| Form 8-K AILERON THERAPEUTICS For: Feb 28 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -1.20% | |
| Aileron Therapeutics and Pulmonary Care Experts To Discuss the Potential Implications of LTI-03 for Idiopathic Pulmonary Fibrosis in Virtual Key Opinion Leader Event | Press release | GlobeNewswire | +0.00% | +4.69% | |
| Form 8-K AILERON THERAPEUTICS For: Feb 09 | SEC filing · Form 8-K | SEC EDGAR | -3.09% | +4.02% | |
| Form EFFECT AILERON THERAPEUTICS | SEC filing · Form EFFECT | SEC EDGAR | — | -7.08% | |
| Aileron Therapeutics to Host Key Opinion Leader Event on February 15, 2024 | Press release | GlobeNewswire | +8.78% | +16.58% | |
| Form DEFA14A AILERON THERAPEUTICS | SEC filing · Form DEFA14A | SEC EDGAR | -0.86% | -6.70% | |
| Form 8-K AILERON THERAPEUTICS For: Jan 29 | SEC filing · Form 8-K | SEC EDGAR | +0.58% | +14.89% | |
| Form ARS AILERON THERAPEUTICS For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +0.58% | +14.89% | |
| Form DEF 14A AILERON THERAPEUTICS For: Feb 28 | SEC filing · Form DEF | SEC EDGAR | +0.58% | +14.89% | |
| Form S-3 AILERON THERAPEUTICS | SEC filing · Form S-3 | SEC EDGAR | -8.93% | -20.71% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the ALRN section they belong to.
Where else ALRN is measured.
ALRN earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| WELLNESS CENTER USA INC (WCUI) | 108 | 0.00% | 24% |
| BAYER AG S/ADR (BAYRY) | 106 | 0.00% | 49% |
| CBA FLORIDA (CBAI) | 105 | 0.00% | 48% |
| GREEN THUMB INDUS SUB VTG (GTBIF) | 105 | +0.08% | 53% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Aileron Therapeutics, Inc.'s median reaction calculated?
Every labeled ALRN news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 105 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 35% of ALRN's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does ALRN's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.